STOCKHOLM, SWEDEN 9 October: On October 3, 2018, the subscription period for Ziccum"s new issue of units was completed, prior to its planned listing on Spotlight. The new issue of 15.8 MSEK was subscribed to approximately 52.7 MSEK including subscription commitments, a subscription ratio of approximately 334%. Ziccum will therefore receive a total of 15.8 MSEK before issue costs of approx. 1 MSEK, while increasing the number of shareholders to approximately 1000. Settlement notes for units subscribed without preference under the new terms and conditions was issued on October 8, 2018.
CEO Göran Conradson’s statement:
"It’s gratifying that the new issue has been fully subscribed and we can now begin speeding up the development of our projects. We believe that Ziccum’s unique technology has significant medical and commercial potential, and I look forward to keeping investors informed as our projects move forward and approach market. I’d like to offer a warm welcome to all Ziccum AB’s new owners!"
Ziccum was founded as a spin-out from Inhalation Sciences, which was successfully noted on Spotlight (formerly Aktietorget) in September 2017. Ziccum"s vision is to enable the delivery of safe and effective drugs to all environments worldwide, minimizing costly and impractical fridge and freezer transport and storage.
Fredersen Advokatbyrå AB has acted as legal adviser in connection with the issue. Aqurat Fondkommission AB has acted as the issuer.
For more information about Ziccum, please contact:
Göran Conradson: CEO Ziccum AB
Mob: +46 709 61 55 99
Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company"s patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets—and open up new ones.